SLNO Soleno Therapeutics | $47.42
-0.1% | 2/4/2025 | Upgraded by | Lifesci Capital | Analyst M. Belghiti | Strong-Buy | | Low | View details for Lifesci Capital rating of Soleno Therapeutics (NASDAQ:SLNO) on 2/4/2025 |
AURA Aura Biosciences | $7.63
-0.3% | 1/31/2025 | Upgraded by | Lifesci Capital | Analyst O. Mccammon | Strong-Buy | | Low | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 1/31/2025 |
JANX Janux Therapeutics | $37.17
-0.4% | 12/27/2024 | Upgraded by | Lifesci Capital | Analyst O. Mccammon | Strong-Buy | | N/A | View details for Lifesci Capital rating of Janux Therapeutics (NASDAQ:JANX) on 12/27/2024 |
MREO Mereo BioPharma Group | $2.87
-1.4% | 12/23/2024 | Upgraded by | Lifesci Capital | Analyst C. Jubinville | Strong-Buy | | N/A | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/23/2024 |
MREO Mereo BioPharma Group | $2.87
-1.4% | 12/24/2024 | Initiated by | Lifesci Capital | - | Outperform | $10.00 | N/A | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/24/2024 |
RPTX Repare Therapeutics | $1.32
| 12/13/2024 | Reiterated by | Lifesci Capital | Analyst C. Zhu | Outperform -> Market Perform | | N/A | View details for Lifesci Capital rating of Repare Therapeutics (NASDAQ:RPTX) on 12/13/2024 |
KURA Kura Oncology | $8.15
-1.7% | 10/22/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | High | View details for Lifesci Capital rating of Kura Oncology (NASDAQ:KURA) on 10/22/2024 |
OKUR OnKure Therapeutics | $5.46
-4.2% | 10/10/2024 | Upgraded by | Lifesci Capital | Analyst S. Slutsky | Strong-Buy | | High | View details for Lifesci Capital rating of OnKure Therapeutics (NASDAQ:OKUR) on 10/10/2024 |
LQDA Liquidia | $16.50
-0.1% | 10/2/2024 | Upgraded by | Lifesci Capital | Analyst C. Jubinville | Strong-Buy | | High | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/2/2024 |
LQDA Liquidia | $16.50
-0.1% | 10/3/2024 | Initiated by | Lifesci Capital | - | Outperform | $30.00 | Low | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/3/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
ORKA Oruka Therapeutics | $11.28
+4.8% | 9/16/2024 | Initiated by | Lifesci Capital | Analyst S. Slutsky | Outperform | $41.00 | Medium | View details for Lifesci Capital rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/16/2024 |
AURA Aura Biosciences | $7.63
-0.3% | 9/9/2024 | Upgraded by | Lifesci Capital | Analyst A. Dhankher | Strong-Buy | | Medium | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 9/9/2024 |
CELC Celcuity | $13.13
-0.2% | 8/26/2024 | Initiated by | Lifesci Capital | Analyst O. Mccammon | Outperform | $27.00 | Low | View details for Lifesci Capital rating of Celcuity (NASDAQ:CELC) on 8/26/2024 |
CRBP Corbus Pharmaceuticals | $8.31
+6.5% | 8/21/2024 | Upgraded by | Lifesci Capital | Analyst M. Belghiti | Strong-Buy | | Low | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 8/21/2024 |
ALXO ALX Oncology | $1.12
-5.9% | 7/31/2024 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Strong-Buy -> Hold | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 7/31/2024 |
RPTX Repare Therapeutics | $1.32
| 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Repare Therapeutics (NASDAQ:RPTX) on 7/29/2024 |
NUVL Nuvalent | $82.39
+2.7% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 7/29/2024 |
MRUS Merus | $47.63
+5.7% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Merus (NASDAQ:MRUS) on 7/29/2024 |
MRSN Mersana Therapeutics | $0.53
-5.2% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of Mersana Therapeutics (NASDAQ:MRSN) on 7/29/2024 |
IDYA IDEAYA Biosciences | $21.75
+5.3% | 7/29/2024 | Upgraded by | Lifesci Capital | Analyst C. Zhu | Strong-Buy | | Low | View details for Lifesci Capital rating of IDEAYA Biosciences (NASDAQ:IDYA) on 7/29/2024 |
DNTH Dianthus Therapeutics | $23.70
+1.5% | 6/11/2024 | Upgraded by | Lifesci Capital | Analyst R. Katkhuda | Strong-Buy | | Low | View details for Lifesci Capital rating of Dianthus Therapeutics (NASDAQ:DNTH) on 6/11/2024 |
CALT Calliditas Therapeutics AB (publ) | $40.00
| 5/28/2024 | Downgraded by | Lifesci Capital | Analyst R. Katkhuda | Strong-Buy -> Hold | | Low | View details for Lifesci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 5/28/2024 |
CATX Perspective Therapeutics | $2.84
-2.7% | 5/6/2024 | Reiterated by | Lifesci Capital | Analyst A. Dhankher | Outperform | | N/A | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 5/6/2024 |
MLYS Mineralys Therapeutics | $9.53
+2.3% | 3/26/2024 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024 |
GPCR Structure Therapeutics | $23.36
-2.1% | 2/27/2024 | Reiterated by | Lifesci Capital | Analyst M. Belghiti | Outperform | | Low | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024 |
VTYX Ventyx Biosciences | $1.66
-1.8% | 2/28/2024 | Upgraded by | Lifesci Capital | Analyst S. Slutsky | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 2/28/2024 |
LRMR Larimar Therapeutics | $3.27
-1.2% | 2/20/2024 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024 |
INBX Inhibrx | $12.80
-0.4% | 1/23/2024 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 1/23/2024 |
IVA Inventiva | $2.73
+0.6% | 1/5/2024 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024 |
TARS Tarsus Pharmaceuticals | $48.72
-1.7% | 12/26/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023 |
RCKT Rocket Pharmaceuticals | $10.87
-0.5% | 12/26/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023 |
SYRE Spyre Therapeutics | $22.41
+0.2% | 12/4/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Spyre Therapeutics (NASDAQ:SYRE) on 12/4/2023 |
TCRX TScan Therapeutics | $2.19
+5.3% | 11/27/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of TScan Therapeutics (NASDAQ:TCRX) on 11/27/2023 |
VTYX Ventyx Biosciences | $1.66
-1.8% | 11/7/2023 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/7/2023 |
VERV Verve Therapeutics | $7.83
-3.0% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 8/8/2023 |
INBX Inhibrx | $12.80
-0.4% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 8/8/2023 |
TNYA Tenaya Therapeutics | $1.13
+0.9% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/8/2023 |
PYXS Pyxis Oncology | $1.36
+0.7% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 4/26/2023 |
OLMA Olema Pharmaceuticals | $5.08
-1.6% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 4/26/2023 |
INBX Inhibrx | $12.80
-0.4% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 4/26/2023 |
Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000” (Ad) Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000.
Should you sit on the sideline while this is happening? That's why we put together a 100% FREE 2025 Gold Guide to show you exactly how to protect and grow y |
AVDL Avadel Pharmaceuticals | $8.47
+0.7% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 4/26/2023 |
ALXO ALX Oncology | $1.12
-5.9% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 4/26/2023 |
IRON Disc Medicine | $54.35
-0.2% | 4/24/2023 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Disc Medicine (NASDAQ:IRON) on 4/24/2023 |
AKRO Akero Therapeutics | $50.58
-0.2% | 4/11/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Akero Therapeutics (NASDAQ:AKRO) on 4/11/2023 |
IFRX InflaRx | $1.85
-2.9% | 4/5/2023 | Upgraded by | Lifesci Capital | - | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 4/5/2023 |
CRNX Crinetics Pharmaceuticals | $36.86
+0.7% | 3/27/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 3/27/2023 |
OBIO Orchestra BioMed | $5.20
-8.8% | 3/8/2023 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | Low | View details for Lifesci Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/8/2023 |
ELVN Enliven Therapeutics | $21.47
-2.0% | 3/7/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Enliven Therapeutics (NASDAQ:ELVN) on 3/7/2023 |
MLTX MoonLake Immunotherapeutics | $42.10
+0.5% | 12/21/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | N/A | View details for Lifesci Capital rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 12/21/2022 |
PYXS Pyxis Oncology | $1.36
+0.7% | 12/1/2022 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 12/1/2022 |
ATXS Astria Therapeutics | $6.82
-2.6% | 11/28/2022 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Astria Therapeutics (NASDAQ:ATXS) on 11/28/2022 |
ALXO ALX Oncology | $1.12
-5.9% | 11/8/2022 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/8/2022 |
VYNE VYNE Therapeutics | $2.70
+7.1% | 8/12/2022 | Downgraded by | Lifesci Capital | Analyst P. Dolezal | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 8/12/2022 |
LRMR Larimar Therapeutics | $3.27
-1.2% | 8/12/2022 | Upgraded by | Lifesci Capital | Analyst P. Dolezal | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/12/2022 |
TNYA Tenaya Therapeutics | $1.13
+0.9% | 6/16/2022 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 6/16/2022 |
VERA Vera Therapeutics | $29.61
+0.3% | 3/28/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Vera Therapeutics (NASDAQ:VERA) on 3/28/2022 |
ELDN Eledon Pharmaceuticals | $4.34
-3.8% | 3/25/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Medium | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/25/2022 |
LRMR Larimar Therapeutics | $3.27
-1.2% | 2/16/2022 | Downgraded by | Lifesci Capital | Analyst Patrick Dolezal | Outperform -> Market Perform | $3.00 | Medium | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/16/2022 |
VERV Verve Therapeutics | $7.83
-3.0% | 12/22/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 12/22/2021 |
ALLK Allakos | $0.29
-0.9% | 12/22/2021 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | High | View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 12/22/2021 |
NNOX Nano-X Imaging | $6.40
-3.5% | 11/17/2021 | Downgraded by | Lifesci Capital | Analyst R. Rakhit | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 11/17/2021 |
VTYX Ventyx Biosciences | $1.66
-1.8% | 11/15/2021 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/15/2021 |
ALXO ALX Oncology | $1.12
-5.9% | 11/4/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/4/2021 |
PYXS Pyxis Oncology | $1.36
+0.7% | 11/2/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 11/2/2021 |
RCKT Rocket Pharmaceuticals | $10.87
-0.5% | 10/24/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/24/2021 |
DRIO DarioHealth | $0.70
+0.1% | 8/26/2021 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | High | View details for Lifesci Capital rating of DarioHealth (NASDAQ:DRIO) on 8/26/2021 |
VRDN Viridian Therapeutics | $16.62
+0.2% | 8/24/2021 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Viridian Therapeutics (NASDAQ:VRDN) on 8/24/2021 |
LRMR Larimar Therapeutics | $3.27
-1.2% | 8/4/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/4/2021 |
OLMA Olema Pharmaceuticals | $5.08
-1.6% | 6/21/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | High | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 6/21/2021 |
NNOX Nano-X Imaging | $6.40
-3.5% | 6/3/2021 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | High | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 6/3/2021 |
ADVM Adverum Biotechnologies | $3.98
-0.5% | 4/29/2021 | Downgraded by | Lifesci Capital | Analyst P. Dolezal | Outperform -> Market Perform | | High | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/29/2021 |
ELDN Eledon Pharmaceuticals | $4.34
-3.8% | 3/18/2021 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | High | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/18/2021 |
COGT Cogent Biosciences | $8.09
+0.1% | 1/4/2021 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | N/A | View details for Lifesci Capital rating of Cogent Biosciences (NASDAQ:COGT) on 1/4/2021 |
CLDX Celldex Therapeutics | $22.59
-2.0% | 11/17/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Celldex Therapeutics (NASDAQ:CLDX) on 11/17/2020 |
TARS Tarsus Pharmaceuticals | $48.72
-1.7% | 11/10/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 11/10/2020 |
AVDL Avadel Pharmaceuticals | $8.47
+0.7% | 11/9/2020 | Reiterated by | Lifesci Capital | Analyst D. Sherman | Outperform | | Low | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/9/2020 |
ADVM Adverum Biotechnologies | $3.98
-0.5% | 11/5/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/5/2020 |
IFRX InflaRx | $1.85
-2.9% | 10/30/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Market Perform | | Low | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 10/30/2020 |
ALLK Allakos | $0.29
-0.9% | 10/22/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 10/22/2020 |
MEIP MEI Pharma | $2.66
-0.7% | 10/21/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of MEI Pharma (NASDAQ:MEIP) on 10/21/2020 |
RCKT Rocket Pharmaceuticals | $10.87
-0.5% | 10/16/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/16/2020 |
INBX Inhibrx | $12.80
-0.4% | 10/15/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 10/15/2020 |
IMVT Immunovant | $20.48
-1.6% | 10/6/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Immunovant (NASDAQ:IMVT) on 10/6/2020 |
VYNE VYNE Therapeutics | $2.70
+7.1% | 10/2/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 10/2/2020 |
ALXO ALX Oncology | $1.12
-5.9% | 9/30/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 9/30/2020 |
CRTX Cortexyme | $1.43
+1.4% | 9/24/2020 | Reiterated by | Lifesci Capital | Analyst D. Sherman | Outperform | | High | View details for Lifesci Capital rating of Cortexyme (NASDAQ:CRTX) on 9/24/2020 |
